A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

Exclusion Criteria

• •Participants are excluded from the study if any of the following criteria apply:
• •Skin co-morbidity that would adversely affect the ability to undertake AD assessments
• •Known history of or suspected significant current immunosuppression
• •Any malignancies or history of malignancies prior to baseline (with the exception of non-melanoma skin cancer excised and cured \>5 years prior to baseline)
• •History of solid organ or stem cell transplant
• •Any active or chronic infection including helminthic infection requiring systemic treatment within 4 weeks prior to baseline
• •Positive for human immunodeficiency virus (HIV), Hepatitis B or hepatitis C at screening visit
• •Having active tuberculosis (TB), latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection, or who are at high risk of contracting TB
• •Having received any of the specified therapy within the specified timeframe(s) prior to the baseline visit
• •In the Investigator's opinion, any clinically significant laboratory results or protocol specified laboratory abnormalities at screening
• •History of hypersensitivity or allergy to any of the excipients or investigational medicinal product (IMP)
• •The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial